Exploration of Chemokine Receptor 4 Targeted [⁶⁸Ga]Ga-pentixafor PET/CT in Radioiodine-refractory Differentiated Thyroid Cancer.

Authors

Yanlin Liu, Hongyuan Dai, Chenyu Sun, Yuewen Sun, Tian Tian, Rui Huang

Published in

Molecular imaging and biology. Aug 21, 2026. Epub Aug 21, 2026.

Abstract

This study compared the diagnostic performance of [¹⁸F]FDG and [⁶⁸Ga]Ga-Pentixafor PET/CT in patients with radioiodine-refractory differentiated thyroid cancer (RAIR-DTC) and assessed clinicopathological characteristics and uptake parameters.
Participants with RAIR-DTC were prospectively enrolled and underwent both [¹⁸F]FDG PET/CT and [⁶⁸Ga]Ga-Pentixafor PET/CT within two weeks. Images were visually and semi-quantitatively analyzed, with lesion number, location, and uptake parameters recorded. The diagnostic performance of the two tracers was compared, and correlations of uptake parameters with clinicopathological characteristics were further evaluated.
Nineteen patients with RAIR-DTC (median age, 60 years) were analyzed. A total of 125 lesions were identified, with 92.8% detected on [¹⁸F]FDG and 89.6% on [⁶⁸Ga]Ga-Pentixafor (P = 0.289). Overall, [¹⁸F]FDG demonstrated higher median SUVmax, tumor-to-background ratio (TBR), and tumor-to-bone marrow ratio (TMR) than [⁶⁸Ga]Ga-Pentixafor (7.33 vs. 3.03; 9.04 vs. 3.11; 4.88 vs. 1.96, respectively; all P < 0.001), while 31.4% (37/118) of lesions detected by at least one tracer showed higher [⁶⁸Ga]Ga-Pentixafor uptake than [¹⁸F]FDG (median SUVmax 4.10 vs. 2.63). Among Pentixafor-positive confirmed lesions, 72.3% had TMR > 1 and 31.3% had TMR > 2. No significant clinicopathological associations with PET parameters were observed.
[⁶⁸Ga]Ga-Pentixafor PET/CT showed no significant difference in lesion detection compared with [¹⁸F]FDG in this RAIR-DTC cohort. Despite lower overall uptake than FDG, one-third of lesions showed higher [⁶⁸Ga]Ga-Pentixafor uptake, and approximately one-third of Pentixafor-positive lesions exhibited TMR greater than two, suggesting that TMR may be an exploratory imaging marker warranting validation for CXCR4-targeted therapy selection.

PMID:
42627462
Bibliographic data and abstract were imported from PubMed on 22 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.